Sign In

Friday, January 19, 2018 - 8:00 am to Saturday, January 20, 2018 - 12:30 pm
Add to Calendar

Conference Description/Needs Statement

This conference will focus on a variety of topics including novel targets and therapies for NASH, chronic hepatitis B, liver cancer, chronic cholestatic liver disease and portal hypertension. New developments in these therapeutic areas will be addressed from the perspective of the practicing hepatologist and the regulatory professional. Attendees will gain insight on new novel pathways involving nuclear hormone receptors and multidrug combination therapies for chronic hepatitis.  Additionally, the development of biomarkers and the design of treatment studies in HCC and NASH will be covered. 

Program Chairs

  • Michael W. Fried, MD, FAASLD
  • Kris V. Kowdley, MD, FACP, FACG, FAASLD

Location

  • Bethesda North Marriott 
    Rockville, MD

Learning Objectives

  • To define current therapeutic targets for chronic liver diseases.
  • To learn about new treatments for NASH, portal HTN, chronic hepatitis B, cholestatic liver disease and liver cancer.
  • To identify current landscape of clinical trials in chronic liver diseases.

Session I: NASH

  • 7 am
    Breakfast
  • 8–8:20 am
    Non-Invasive Assessment of NASH: F-NIH and Other Initiatives
    Arun J. Sanyal, MD, FAASLD
  • 8:20–8:40 am
    Introducing NASH-related Health Measures in Population Health Studies
    Zobair M. Younossi, MD, MPH, FAASLD
  • 8:40–9 am
    Demonstrating Effectiveness of NASH Interventions and Road to Combination Therapies
    Stephen A. Harrison, MD, FAASLD
  • 9–9:20 am
    Prioritizing NASH Treatments: Lessons from HCV 
    Mary E. Rinella, MD, FAASLD
  • 9:20–9:50 am
    Panel Discussion
  • 9:50–10:20 am
    Break

Session II: Cholestatic Liver Diseases

Moderators: Cynthia Levy, MD, FAASLD and David Jones, PhD

  • 10:20–10:40 am
    Pathways and Targets of Cholestatic Liver Disease
    David Jones, PhD
  • 10:40–11 am
    Current Drug Development for PBC and Primary Sclerosing Cholangitis
    Michael H. Trauner, MD, FAASLD
  • 11–11:20 am
    Screening and Management of Cholangiocarcinoma
    Julie Heimbach, MD 
  • 11:20–11:40 am
    Surrogate End-Points for Drug Development in Cholestatic Disorders
    Cynthia Levy, MD, FAASLD 
  • 11:40 am–12:10 pm
    Panel Discussion
  • 12:15–1:45 pm
    Lunch and Poster Viewing

Session III: Portal HTN

Moderators: Guadalupe Garcia-Tsao, MD, FAASLD and Juan G. Abraldes, MD

  • 1:45–2:05 pm
    Candidate Therapeutic Target and Drugs-Experimental Models
    Jonel Trebicka, MD, PhD
  • 2:05–2:25 pm
    Candidate Drugs: Human Studies
    Guadalupe Garcia-Tsao, MD, FAASLD
  • 2:25–2:45 pm
    Clinical Trial Design in Portal HTN
    Juan G. Abraldes, MD
  • 2:45–3:15 pm
    Panel Discussion
  • 3:15–3:45 pm
    Break

Session IV: Cirrhosis

Moderators: Meena B. Bansal, MD and Naga P. Chalasani, MD, FAASLD

  • 3:45–4:05 pm 
    Assessment of PK/PD and Toxicity in Cirrhotic Patients
    Naga P. Chalasani, MD, FAASLD
  • 4:05–4:25 pm 
    Intermediate Surrogate Markers for Therapeutic Response in Patients with Cirrhosis
    Meena B. Bansal, MD
  • 4:25–4:45 pm 
    Assessing Long-term Outcomes After Therapeutic Interventions in Patients with Cirrhosis
    Joseph K. Lim, MD, FAASLD
  • 4:45–5:15 pm 
    Panel Discussion

Session IV: Cirrhosis

Moderators: Meena B. Bansal, MD and Naga P. Chalasani, MD, FAASLD

  • 3:45–4:05 pm
    Assessment of PK/PD and Toxicity in Cirrhotic Patients
    Naga P. Chalasani, MD, FAASLD
  • 4:05–4:25 pm
    Intermediate Surrogate Markers for Therapeutic Response in Patients with Cirrhosis
    Meena B. Bansal, MD
  • 4:25–4:45 pm
    Assessing Long-term Outcomes After Therapeutic Interventions in Patients with Cirrhosis
    Joseph K. Lim, MD, FAASLD
  • 4:45–5:15 pm
    Panel Discussion